

Giuseppe Orefice

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5822143/publications.pdf>

Version: 2024-02-01

43
papers

6,216
citations

257101

24
h-index

264894

42
g-index

43
all docs

43
docs citations

43
times ranked

4405
citing authors

#	ARTICLE	IF	CITATIONS
1	Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study. <i>Cephalalgia</i> , 1988, 8, 1-6.	1.8	4,583
2	Grey matter loss in relapsing-remitting multiple sclerosis: A voxel-based morphometry study. <i>NeuroImage</i> , 2006, 29, 859-867.	2.1	167
3	The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. <i>PLoS ONE</i> , 2013, 8, e70244.	1.1	150
4	Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. <i>Journal of the Neurological Sciences</i> , 2007, 263, 15-19.	0.3	130
5	Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke. <i>Stroke</i> , 2002, 33, 51-56.	1.0	112
6	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855.	1.8	83
7	Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. <i>NeuroImage</i> , 2003, 18, 360-366.	2.1	82
8	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 450-454.	1.4	79
9	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854.	1.1	60
10	Levetiracetam for cerebellar tremor in multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 762-766.	1.8	56
11	Post-exercise facilitation and depression of motor evoked potentials to transcranial magnetic stimulation: a study in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2004, 115, 2128-2133.	0.7	54
12	Multiple sclerosis and headache co-morbidity. A case-control study. <i>Neurological Sciences</i> , 2007, 28, 133-135.	0.9	54
13	Epileptic seizures in multiple sclerosis: clinical and EEG correlations. <i>Neurological Sciences</i> , 2003, 24, 322-328.	0.9	49
14	A voxel-based morphometry study of disease severity correlates in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 45-54.	1.4	45
15	Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon- β 1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016, 13, 428-438.	2.1	43
16	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014, 35, 379-383.	0.9	42
17	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon- β 2. <i>Journal of the Neurological Sciences</i> , 2006, 244, 97-102.	0.3	40
18	COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS. <i>Neurology</i> , 2009, 73, 1078-1079.	1.5	40

#	ARTICLE	IF	CITATIONS
19	Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon- β . BMC Medical Genomics, 2014, 7, 26.	0.7	36
20	Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. European Journal of Neurology, 2006, 13, 1014-1021.	1.7	30
21	Age-Related Risk Factors for Ischemic Stroke in Italian Men. Neuroepidemiology, 1994, 13, 28-33.	1.1	27
22	Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. Journal of the Neurological Sciences, 2006, 245, 141-145.	0.3	27
23	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. Clinical Neuropharmacology, 2008, 31, 167-172.	0.2	25
24	Natalizumab vs interferon beta 1a in relapsing-relmitting multiple sclerosis: a head-to-head retrospective study. Acta Neurologica Scandinavica, 2012, 126, 306-314.	1.0	25
25	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	1.4	24
26	Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurological Sciences, 2013, 34, 521-528.	0.9	20
27	Prognostic Value of Combined Target-Organ Damage in Patients With Essential Hypertension. American Journal of Hypertension, 2015, 28, 127-134.	1.0	18
28	Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-relmitting and secondary progressive multiple sclerosis patients. European Journal of Neurology, 2011, 18, 1402-1406.	1.7	17
29	Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Multiple Sclerosis Journal, 2009, 15, 204-211.	1.4	16
30	Microalbuminuria predicts the recurrence of cardiovascular events in patients with essential hypertension. Journal of Hypertension, 2016, 34, 646-653.	0.3	14
31	Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family. Journal of Neurology, 2014, 261, 823-824.	1.8	13
32	The IFN- β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-relmitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells. Brain Research Bulletin, 2015, 118, 1-6.	1.4	13
33	Transient Muteness Followed by Dysarthria in Patients with Pontomesencephalic Stroke. Cerebrovascular Diseases, 1999, 9, 124-126.	0.8	11
34	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. Journal of Neural Transmission, 2016, 123, 371-377.	1.4	9
35	Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. Journal of the Neurological Sciences, 2013, 331, 172-173.	0.3	6
36	Effect of diabetes on some primitive reflexes. European Journal of Neurology, 2000, 7, 401-404.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. <i>Neurological Sciences</i> , 2011, 32, 287-292.	0.9	4
38	Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: results of a randomized controlled trial. <i>Current Therapeutic Research</i> , 2002, 63, 337-343.	0.5	2
39	Movement disorders as presenting symptoms of AIDS. <i>Basal Ganglia</i> , 2013, 3, 175-178.	0.3	2
40	Serpentine tongue in long-term metoclopramide treatment. <i>Neurology Psychiatry and Brain Research</i> , 2014, 20, 93-95.	2.0	2
41	Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature. <i>Pharmacology & Pharmacy</i> , 2012, 03, 248-253.	0.2	1
42	Recurrent pulmonary and cerebral thromboembolism in an adult patients following incomplete removal of ventriculoatrial shunt for congenital hydrocephalus. <i>BMJ Case Reports</i> , 2009, 2009, bcr0320091645-bcr0320091645.	0.2	1
43	Diagnostic challenges of Parkinsonism occurring in multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2015, 115, 513-515.	0.5	0